Related references
Note: Only part of the references are listed.Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies
Reinhard Marks et al.
BLOOD (2008)
CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine
K. Raj et al.
LEUKEMIA (2007)
Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7
Bjoern Rueter et al.
BLOOD (2007)
End points to establish the efficacy of new agents in the treatment of acute leukemia
Frederick R. Appelbaum et al.
BLOOD (2007)
Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine
Thorsten Graef et al.
LEUKEMIA RESEARCH (2007)
Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study
H Kantarjian et al.
CANCER (2006)
Fatal varicella zoster virus encephalitis in two patients following allogeneic hematopoietic stem cell transplantation
B Hackanson et al.
CLINICAL TRANSPLANTATION (2005)
Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2 '-deoxycytidine
AR Karpf et al.
MOLECULAR PHARMACOLOGY (2004)
5-Aza-2′-deoxycytidine (decitabine) treatment of hematopoietic malignancies:: a multimechanism therapeutic approach?
L Sigalotti et al.
BLOOD (2003)
Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia
H Bertz et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias
M de Lima et al.
CANCER (2003)
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm
S Fröhling et al.
BLOOD (2002)